advancing innovation to save lives

GHTC fact sheet looks at role of R&D in advancing universal health coverage

GHTC released a new fact sheet examining how R&D of new drugs, vaccines, diagnostics, and other tools is a critical driver of universal health coverage. The resource looks at out how new and improved technologies can help expand access to care in low-resource communities, fill urgent treatment and prevention gaps to improve quality of care, overcome barriers to care among vulnerable populations, and generate health care system cost savings.

GHTC unveils new report on global health innovation at USAID

GHTC unveiled a new report examing how the US Agency for International Development’s (USAID) investments in global health innovation are an essential enabler in accelerating partner countries along the journey to self-reliance. It explores challenges and opportunities the agency faces in advancing this work and provides actionable recommendations for the administration and Congress to maximize the agency's health research and development activities.

Member Spotlight: Medicines for Malaria Venture

MMV is a leading product development partnership in antimalarial drug research celebrating its 20th anniversary in November. Since foundation in 1999, MMV and partners have developed and brought forward eleven new medicines estimated to have saved 1.9 million lives from malaria.

Learn More

GHTC works to save and improve lives by encouraging the research and development of essential health technologies. We bring together more than 25 nonprofit organizations, academic institutions, and aligned businesses to advance policies to accelerate the creation of new drugs, vaccines, diagnostics, and other tools that bring healthy lives within reach for all people.

Why we're needed

Health technologies have the potential to save millions of lives. New tools are needed to slow the global threat of diseases, including HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases, and tackle many other pressing health needs. For diseases and conditions primarily affecting people in the world’s poorest places, there is little to no commercial market to spur R&D. Strong investment and innovative solutions are needed to catalyze the development of new technologies to bring health and opportunity within reach for all people.

Learn more

PATH/Matthew Dakin
GHTC sends FY21 letter to OMB

GHTC sent a letter to the White House Office of Management and Budget (OMB), calling for the administration to sustain and protect global health R&D in the fiscal year 2021 (FY21) budget.


PATH/Matthew Dakin
GHTC op-ed featured in The Hill

A commentary piece authored by GHTC Director Jamie Bay Nishi on the steady and substantial funding necessary to drive breakthrough innovations for global health threats was featured in The Hill

View All News & Events

Community Event

PATH/Gabe Bienczycki
World Health Summit 2019
World Health Summit
Learn More

Community Event

PATH/Eric Becker
World Infectious and Rare Diseases Congress
Scientific Future Group
Learn More
View All Events
PATH/Algy Amad
Research Roundup: Pregnant women in DRC to be given Ebola vaccine, releases of genetically modified mosquitoes in high-security lab, and CRISPR may help against viruses for which no vaccine exists

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
Flickr/United States Mission Geneva, Eric Bridiers
WHO EB moves forward actions on budget, access to medicines, and AMR R&D

The 2019 global health multilateral calendar kicked off as it always does with the World Health Organization (WHO) Executive Board (EB) meeting in late January in Geneva. This year’s session featured a packed agenda with significant implications for research and development.

Read More
View Breakthroughs Blog

Our members work to improve health worldwide